Cargando…

AI Model for Prostate Biopsies Predicts Cancer Survival

An artificial intelligence (AI) algorithm for prostate cancer detection and grading was developed for clinical diagnostics on biopsies. The study cohort included 4221 scanned slides from 872 biopsy sessions at the HUS Helsinki University Hospital during 2016–2017 and a subcohort of 126 patients trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandeman, Kevin, Blom, Sami, Koponen, Ville, Manninen, Anniina, Juhila, Juuso, Rannikko, Antti, Ropponen, Tuomas, Mirtti, Tuomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139241/
https://www.ncbi.nlm.nih.gov/pubmed/35626187
http://dx.doi.org/10.3390/diagnostics12051031
_version_ 1784714813437378560
author Sandeman, Kevin
Blom, Sami
Koponen, Ville
Manninen, Anniina
Juhila, Juuso
Rannikko, Antti
Ropponen, Tuomas
Mirtti, Tuomas
author_facet Sandeman, Kevin
Blom, Sami
Koponen, Ville
Manninen, Anniina
Juhila, Juuso
Rannikko, Antti
Ropponen, Tuomas
Mirtti, Tuomas
author_sort Sandeman, Kevin
collection PubMed
description An artificial intelligence (AI) algorithm for prostate cancer detection and grading was developed for clinical diagnostics on biopsies. The study cohort included 4221 scanned slides from 872 biopsy sessions at the HUS Helsinki University Hospital during 2016–2017 and a subcohort of 126 patients treated by robot-assisted radical prostatectomy (RALP) during 2016–2019. In the validation cohort (n = 391), the model detected cancer with a sensitivity of 98% and specificity of 98% (weighted kappa 0.96 compared with the pathologist’s diagnosis). Algorithm-based detection of the grade area recapitulated the pathologist’s grade group. The area of AI-detected cancer was associated with extra-prostatic extension (G5 OR: 48.52; 95% CI 1.11–8.33), seminal vesicle invasion (cribriform G4 OR: 2.46; 95% CI 0.15–1.7; G5 OR: 5.58; 95% CI 0.45–3.42), and lymph node involvement (cribriform G4 OR: 2.66; 95% CI 0.2–1.8; G5 OR: 4.09; 95% CI 0.22–3). Algorithm-detected grade group 3–5 prostate cancer depicted increased risk for biochemical recurrence compared with grade groups 1–2 (HR: 5.91; 95% CI 1.96–17.83). This study showed that a deep learning model not only can find and grade prostate cancer on biopsies comparably with pathologists but also can predict adverse staging and probability for recurrence after surgical treatment.
format Online
Article
Text
id pubmed-9139241
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91392412022-05-28 AI Model for Prostate Biopsies Predicts Cancer Survival Sandeman, Kevin Blom, Sami Koponen, Ville Manninen, Anniina Juhila, Juuso Rannikko, Antti Ropponen, Tuomas Mirtti, Tuomas Diagnostics (Basel) Article An artificial intelligence (AI) algorithm for prostate cancer detection and grading was developed for clinical diagnostics on biopsies. The study cohort included 4221 scanned slides from 872 biopsy sessions at the HUS Helsinki University Hospital during 2016–2017 and a subcohort of 126 patients treated by robot-assisted radical prostatectomy (RALP) during 2016–2019. In the validation cohort (n = 391), the model detected cancer with a sensitivity of 98% and specificity of 98% (weighted kappa 0.96 compared with the pathologist’s diagnosis). Algorithm-based detection of the grade area recapitulated the pathologist’s grade group. The area of AI-detected cancer was associated with extra-prostatic extension (G5 OR: 48.52; 95% CI 1.11–8.33), seminal vesicle invasion (cribriform G4 OR: 2.46; 95% CI 0.15–1.7; G5 OR: 5.58; 95% CI 0.45–3.42), and lymph node involvement (cribriform G4 OR: 2.66; 95% CI 0.2–1.8; G5 OR: 4.09; 95% CI 0.22–3). Algorithm-detected grade group 3–5 prostate cancer depicted increased risk for biochemical recurrence compared with grade groups 1–2 (HR: 5.91; 95% CI 1.96–17.83). This study showed that a deep learning model not only can find and grade prostate cancer on biopsies comparably with pathologists but also can predict adverse staging and probability for recurrence after surgical treatment. MDPI 2022-04-20 /pmc/articles/PMC9139241/ /pubmed/35626187 http://dx.doi.org/10.3390/diagnostics12051031 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sandeman, Kevin
Blom, Sami
Koponen, Ville
Manninen, Anniina
Juhila, Juuso
Rannikko, Antti
Ropponen, Tuomas
Mirtti, Tuomas
AI Model for Prostate Biopsies Predicts Cancer Survival
title AI Model for Prostate Biopsies Predicts Cancer Survival
title_full AI Model for Prostate Biopsies Predicts Cancer Survival
title_fullStr AI Model for Prostate Biopsies Predicts Cancer Survival
title_full_unstemmed AI Model for Prostate Biopsies Predicts Cancer Survival
title_short AI Model for Prostate Biopsies Predicts Cancer Survival
title_sort ai model for prostate biopsies predicts cancer survival
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139241/
https://www.ncbi.nlm.nih.gov/pubmed/35626187
http://dx.doi.org/10.3390/diagnostics12051031
work_keys_str_mv AT sandemankevin aimodelforprostatebiopsiespredictscancersurvival
AT blomsami aimodelforprostatebiopsiespredictscancersurvival
AT koponenville aimodelforprostatebiopsiespredictscancersurvival
AT manninenanniina aimodelforprostatebiopsiespredictscancersurvival
AT juhilajuuso aimodelforprostatebiopsiespredictscancersurvival
AT rannikkoantti aimodelforprostatebiopsiespredictscancersurvival
AT ropponentuomas aimodelforprostatebiopsiespredictscancersurvival
AT mirttituomas aimodelforprostatebiopsiespredictscancersurvival